LOGO
LOGO

Intraday Alerts

Atara Biotherapeutics Stock Gains 42% Over Regulatory Update About Tabelecleucel

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News

Shares of Atara Biotherapeutics, Inc. (ATRA) are gaining about 42 percent in Thursday morning trading after the company announced a regulatory update following a recent Type A meeting with the U.S. FDA to discuss the Complete Response Letter issued for the Biologics License Application for Tabelecleucel.

The company's shares are currently trading at $7.31 on the Nasdaq, up 42.45 percent. The stock opened at $7.85 and has climbed as high as $7.89 so far in today's session. Over the past year, it has traded in a range of $3.92 to $19.15.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update - May 04 – May 08, 2026

May 08, 2026 15:50 ET
Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.

Latest Updates on COVID-19